A Phase 2 interventional study of Omaveloxolone Capsules, 2.5 mg and Omaveloxolone Capsules, 5 mg in Friedreich Ataxia, sponsored by Biogen. Completed at 11 sites in 5 countries. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.
Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 2nd largest by enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2015, is one of 14 in phase 2, and was the 18th registered.
111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.
Browse Friedreich Ataxia studies →18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 16+ · Women only
Larimar Therapeutics, Inc. · Sites in United States
Ages 12–40
Scott Barbuto · Sites in United States
Lexeo Therapeutics · Sites in United States
Ages 6+
Solid Biosciences Inc. · Sites in United States
Ages 18–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 12
First in 2001; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 30 across 76 interventional studies indexed under Friedreich Ataxia.
Median enrollment 32 across the 49 interventional studies, 65 across the 21 observational. Of the 43 that completed or were terminated, 16 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 71 have an industry lead sponsor. The 10 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Biogen has 6 studies filed under Friedreich Ataxia — fewer than ten, so there is no comparison to draw.
6 of the studies in Friedreich Ataxia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953583Phase 3BiogenA Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | 2027-11-16 |
| NCT06447025Larimar Therapeutics, Inc.An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | 2027-01 |
| NCT07869654Adjuvia Therapeutics, Inc.A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults | 2027-05-27 |
| NCT07870590Graviton Bioscience CorporationGV101 for Friedreich's Ataxia (FA) Treatment | 2027-07 |
| NCT02316314Weill Medical College of Cornell UniversityCharacterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA) | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 71 studies in Friedreich Ataxia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The main goal of this study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily life.
The main questions researchers want to answer in this study are:
Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work.
They will also use a cycling test to measure physical effort, along with questionnaires to learn how participants feel and function in daily life.
Safety will also be tested using physical exams, vital sign checks, echocardiograms (ECHO), electrocardiograms (ECG), and blood and urine tests.
The study will be done in 2 main parts, followed by an optional Extension period:
Friedreich's ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an increased sensitivity to oxidative stress.
A hallmark of Friedreich's ataxia is impairment of antioxidative defense mechanisms, which play a major role in disease progression. Studies have demonstrated that nuclear factor erythroid-derived 2-related factor 2 (Nrf2) signaling is grossly impaired in participants with Friedreich's ataxia. Therefore, the ability of omaveloxolone (RTA 408) to activate Nrf2 and induce antioxidant target genes is hypothesized to be therapeutic in participants with Friedreich's ataxia.
This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone (RTA 408) in the treatment of participants with Friedreich's ataxia.
Part 1: The first part of this study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in participants with Friedreich's ataxia.
Part 2: The second part of this study is a randomized, placebo-controlled, double-blind, parallel-group study to evaluate the safety and efficacy of omaveloxolone (RTA 408) 150 mg in participants with Friedreich's ataxia. Participants enrolled in Part 2 will be randomized 1:1 to receive omaveloxolone (RTA 408) 150 mg or placebo.
Extension: The extension will assess long-term safety and tolerability of omaveloxolone (RTA 408) in qualified participants with Friedreich's ataxia following completion of Part 1 or Part 2. Participants will not be unblinded to study treatment in Part 1 or Part 2 upon entering the extension study. Participants will receive open-label omaveloxolone (RTA 408) at 150 mg once daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received omaveloxolone 2.5 mg, oral capsule, QD for 2 weeks, followed by 5 mg Omaveloxolone, oral capsule, QD for 10 weeks.
Drug: Omaveloxolone Capsules, 2.5 mg · Drug: Omaveloxolone Capsules, 5 mg
Participants received omaveloxolone 10 mg, oral capsule, QD for 12 weeks.
Drug: Omaveloxolone Capsules, 10 mg
Participants received omaveloxolone 20 mg, oral capsule, QD for 12 weeks.
Drug: Omaveloxolone Capsules, 20 mg
Participants received omaveloxolone 40 mg, oral capsule, QD for 12 weeks.
Drug: Omaveloxolone Capsules, 40 mg
Participants received omaveloxolone 80 mg, oral capsule, QD for 12 weeks.
Drug: Omaveloxolone Capsules, 80 mg
Participants received omaveloxolone 160 mg, oral capsule, QD for 12 weeks.
Drug: Omaveloxolone Capsules, 160 mg
Participants received omaveloxolone 300 mg, oral capsule, QD for 12 weeks.
Drug: Omaveloxolone Capsules, 300 mg
Participants received placebo, oral capsule, QD for 12 weeks.
Drug: Placebo
Participants received omaveloxolone 150 mg, oral capsule, QD for 48 weeks.
Drug: Omaveloxolone Capsules, 150 mg
Participants received placebo, oral capsule, QD for 48 weeks.
Drug: Placebo
All eligible participants who had received either omaveloxone or placebo in Part 1 and eligible participants who received placebo in Part 2 received omaveloxone, 150 mg, oral capsule, QD, until the drug was available through commercial channels or alternate post-trial access mechanisms, or until participant withdrawal, whichever was sooner (up to approximately 370 weeks).
Drug: Omaveloxolone Capsules, 150 mg
All eligible participants who had received omaveloxone in Part 2 continued to receive omaveloxolone, 150 mg, oral capsule, QD until the drug was available through commercial channels or alternate post-trial access mechanisms, or until participant withdrawal, whichever was sooner (up to approximately 370 weeks).
Drug: Omaveloxolone Capsules, 150 mg
Also known as: RTA 408 Capsules 2.5 mg
Also known as: RTA 408 capsules, 5 mg
Also known as: RTA 408 capsules, 10 mg
Also known as: RTA 408 capsules, 20 mg
Also known as: RTA 408 capsules, 40 mg
Also known as: RTA 408 capsules, 80 mg
Also known as: RTA 408 capsules, 160 mg
Also known as: RTA 408 capsules, 300 mg
Also known as: RTA 408 capsules, 150 mg
Part 1: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 12
Cycle ergometry using a recumbent stationary bicycle was used to conduct maximal exercise testing and workload was increased incrementally. Peak work is defined as the workload at which participants reach maximal volition (defined as an inability to continue to exercise due to exhaustion). A positive change from baseline suggests an improvement.
Time frame: Baseline, Week 12
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any unfavorable and unintended sign (including any clinically significant abnormal laboratory test result), symptom, or disease temporally associated with the use of the study drug whether or not it is considered to be study drug related. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as any AEs, regardless of relationship to study drug, that had an onset or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug up to end of Part 1 of the study (up to Week 16)
Part 2: Change From Baseline in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48
The Friedreich Ataxia Rating Scale (FARS) is a neurological-exam-based rating scale with five sections: Bulbar (section A), Upper Limb Coordination (section B), Lower Limb Coordination (section C), Peripheral Nervous System (section D), and Upright Stability (section E). mFARS is the sum of sections A (score 0 to 11), B (score 0 to 36), C (score 0 to 16), and E (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.
Time frame: Baseline, Week 48
Part 2: Number of Participants With TEAEs and TESAEs
An AE was any unfavorable and unintended sign (including any clinically significant abnormal laboratory test result), symptom, or disease temporally associated with the use of the study drug whether or not it is considered to be study drug related. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as any AEs, regardless of relationship to study drug, that had an onset or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug up to end of Part 2 of the study (up to Week 52)
Part 1: Change From Baseline in the mFARS at Week 12
The FARS is a neurological-exam-based rating scale with five sections: Bulbar (section A), Upper Limb Coordination (section B), Lower Limb Coordination (section C), Peripheral Nervous System (section D), and Upright Stability (section E). mFARS is the sum of sections A (score 0 to 11), B (score 0 to 36), C (score 0 to 16), and E (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.
Time frame: Baseline, Week 12
Part 2: Number of Participants With Patient Global Impression of Change (PGI-C)
The PGI-C is a 7-point scale that requires participants to assess how much their illness has improved or worsened relative to their baseline state at the beginning of the trial. Participants self-rated their perceived change by completing the following statement: "Since I began trial treatment, my overall status is:" 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse and 7=Very much worse. Lower score indicates better improvement. The categories with at least one participant having a PGI-C score are reported.
Time frame: Week 48
Part 2: Number of Participants With Clinical Global Impression of Change (CGI-C)
The CGIC scale is a 7 point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of an intervention. The CGIC was assessed by completing the following statement "Compared to the participant's condition at the start of the trial, this participant's overall status is", where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. Lower score indicates better improvement. The categories with at least one participant having a CGIC score are reported.
Time frame: Week 48
Part 2: Change From Baseline in Performance on a 9-Hole Peg Test (9-HPT) at Week 48
The 9-HPT is a brief, standardized, quantitative test of upper extremity (arm and hand) function. Both the dominant and nondominant hands were tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand). The participant picks up pegs 1 at a time (9 in total), using 1 hand only, and places them into holes on the board as quickly as possible, in any order until all holes are filled. Then, without pausing, the participant removes the pegs 1 at a time and returns them as quickly as possible. The times recorded for the two trials for each hand are averaged, and the reciprocal average value for each hand was used in analyses. Longer test times reflect more impairment on the participant's upper extremity function, thus a negative change from baseline suggests an improvement.
Time frame: Baseline, Week 48
Part 2: Change From Baseline in Performance on a 25-Foot Timed Walk Test (T25-FWT) at Week 48
The T25-FWT is a quantitative mobility and leg function performance test based on time (in seconds) to complete a 25-foot walk. Participants were instructed to attempt two T25-FWT trials at each visit. Both walk times were averaged, and the reciprocal average value was used in analyses. Longer test times reflect more impairment on the participant's ability to walk, thus a negative change from baseline suggests an improvement.
Time frame: Baseline, Week 48
Part 2: Total Number of Falls
A fall was defined as "the participant unintentionally coming to rest on the ground or at a lower level." The total number of falls before and after study drug administration has been reported.
Time frame: Up to Week 48
Part 2: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 48
Cycle ergometry using a recumbent stationary bicycle was used to conduct maximal exercise testing and workload was increased incrementally. Peak work is defined as the workload at which participants reach maximal volition (defined as an inability to continue to exercise due to exhaustion). A positive change from baseline suggests an improvement.
Time frame: Baseline, Week 48
Part 2: Change From Baseline in the Activities of Daily Living (ADL) Score at Week 48
The ADL scale examines the ability of participants to complete everyday tasks (e.g., holding a fork, dressing). The ADL is a 9-question assessment, with the total score being the sum of 9 questions. The ADL survey assesses 9 concepts: (1) speech; (2) swallowing; (3) cutting food and handling utensils; (4) dressing; (5) personal hygiene; (6) falling; (7) walking; (8) quality of sitting position; and (9) bladder function. Each of these is rated on a 5-point scale where 0= normal and 4= severe disability/inability to carry out activity independently, for a total possible score of 0 to 36, with higher scores representing greater disability/dependency. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 48
Participants took part in the study at multiple investigative sites from 31 January 2015 to 19 December 2025.
| Milestone | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | OLE: Placebo/ Omaveloxolone | OLE: Omaveloxolone/ Omaveloxolone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 12 | 10 | 17 | 0 | 0 | 0 | 0 |
| Number of participants with pes cavus | 2 | 2 | 3 | 2 | 2 | 8 | 3 | 10 | 0 | 0 | 0 | 0 |
| Completed | 6 | 6 | 6 | 6 | 6 | 12 | 10 | 16 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | OLE: Placebo/ Omaveloxolone | OLE: Omaveloxolone/ Omaveloxolone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 51 | 52 | 0 | 0 |
| Number of participants with pes cavus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 10 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45 | 51 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 0 |
| Withdrew: Administrative reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 |
| Milestone | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | OLE: Placebo/ Omaveloxolone | OLE: Omaveloxolone/ Omaveloxolone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 106 | 43 |
| Part 1: randomized to placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 0 |
| Part 1: randomized to omaveloxolone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44 | 0 |
| Part 2: randomized to placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49 | 0 |
| Part 2: randomized to omaveloxolone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 34 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 9 |
| Withdrew: Administrative reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 5 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 4 |
Cycle ergometry using a recumbent stationary bicycle was used to conduct maximal exercise testing and workload was increased incrementally. Peak work is defined as the workload at which participants reach maximal volition (defined as an inability to continue to exercise due to exhaustion). A positive change from baseline suggests an improvement.
| Watts per kilogram (W/kg) | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo |
|---|---|---|---|---|---|---|---|---|
| Part 1: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 12 | 0.14 (0.02 to 0.26) | 0.07 (-0.05 to 0.18) | -0.09 (-0.20 to 0.03) | 0.06 (-0.06 to 0.18) | 0 (-0.11 to 0.12) | 0.02 (-0.06 to 0.10) | 0.07 (-0.02 to 0.17) | 0.04 (-0.03 to 0.11) |
An adverse event (AE) was any unfavorable and unintended sign (including any clinically significant abnormal laboratory test result), symptom, or disease temporally associated with the use of the study drug whether or not it is considered to be study drug related. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as any AEs, regardless of relationship to study drug, that had an onset or worsened in severity on or after the first dose of study drug.
| Participants | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo |
|---|---|---|---|---|---|---|---|---|
| TEAEs | 6 | 5 | 5 | 6 | 6 | 11 | 10 | 16 |
| TESAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
The Friedreich Ataxia Rating Scale (FARS) is a neurological-exam-based rating scale with five sections: Bulbar (section A), Upper Limb Coordination (section B), Lower Limb Coordination (section C), Peripheral Nervous System (section D), and Upright Stability (section E). mFARS is the sum of sections A (score 0 to 11), B (score 0 to 36), C (score 0 to 16), and E (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.
| score on a scale | Part 2 Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48 | -1.45 ± 4.209 | 0.90 ± 4.305 |
An AE was any unfavorable and unintended sign (including any clinically significant abnormal laboratory test result), symptom, or disease temporally associated with the use of the study drug whether or not it is considered to be study drug related. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as any AEs, regardless of relationship to study drug, that had an onset or worsened in severity on or after the first dose of study drug.
| Participants | Part 2: Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| TEAEs | 51 | 52 |
| TESAEs | 5 | 3 |
The FARS is a neurological-exam-based rating scale with five sections: Bulbar (section A), Upper Limb Coordination (section B), Lower Limb Coordination (section C), Peripheral Nervous System (section D), and Upright Stability (section E). mFARS is the sum of sections A (score 0 to 11), B (score 0 to 36), C (score 0 to 16), and E (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.
| score on a scale | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo |
|---|---|---|---|---|---|---|---|---|
| Part 1: Change From Baseline in the mFARS at Week 12 | -3.26 (-5.82 to -0.70) | -1.97 (-4.53 to 0.59) | -2.44 (-5.00 to 0.12) | -2.4 (-4.96 to 0.16) | -2.88 (-5.44 to -0.31) | -3.75 (-5.56 to -1.94) | -0.88 (-2.86 to 1.11) | -1.43 (-2.97 to 0.11) |
The PGI-C is a 7-point scale that requires participants to assess how much their illness has improved or worsened relative to their baseline state at the beginning of the trial. Participants self-rated their perceived change by completing the following statement: "Since I began trial treatment, my overall status is:" 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse and 7=Very much worse. Lower score indicates better improvement. The categories with at least one participant having a PGI-C score are reported.
| Participants | Part 2: Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| Very Much Improved | 1 | 1 |
| Much Improved | 3 | 2 |
| Minimally Improved | 12 | 8 |
| No Change | 9 | 13 |
| Minimally Worse | 9 | 12 |
| Much Worse | 2 | 5 |
The CGIC scale is a 7 point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of an intervention. The CGIC was assessed by completing the following statement "Compared to the participant's condition at the start of the trial, this participant's overall status is", where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. Lower score indicates better improvement. The categories with at least one participant having a CGIC score are reported.
| Participants | Part 2: Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| Much Improved | 2 | 2 |
| Minimally Improved | 12 | 10 |
| No Change | 15 | 17 |
| Minimally Worse | 8 | 11 |
| Much Worse | 0 | 1 |
The 9-HPT is a brief, standardized, quantitative test of upper extremity (arm and hand) function. Both the dominant and nondominant hands were tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand). The participant picks up pegs 1 at a time (9 in total), using 1 hand only, and places them into holes on the board as quickly as possible, in any order until all holes are filled. Then, without pausing, the participant removes the pegs 1 at a time and returns them as quickly as possible. The times recorded for the two trials for each hand are averaged, and the reciprocal average value for each hand was used in analyses. Longer test times reflect more impairment on the participant's upper extremity function, thus a negative change from baseline suggests an improvement.
| 1/second | Part 2: Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| Dominant Hand | -0.0001 ± 0.00300 | -0.0009 ± 0.00338 |
| Non-Dominant Hand | -0.0013 ± 0.00512 | -0.0003 ± 0.00298 |
The T25-FWT is a quantitative mobility and leg function performance test based on time (in seconds) to complete a 25-foot walk. Participants were instructed to attempt two T25-FWT trials at each visit. Both walk times were averaged, and the reciprocal average value was used in analyses. Longer test times reflect more impairment on the participant's ability to walk, thus a negative change from baseline suggests an improvement.
| 1/second | Part 2: Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Performance on a 25-Foot Timed Walk Test (T25-FWT) at Week 48 | -0.0175 ± 0.02716 | -0.0221 ± 0.03294 |
A fall was defined as "the participant unintentionally coming to rest on the ground or at a lower level." The total number of falls before and after study drug administration has been reported.
| number of falls | Part 2: Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| Part 2: Total Number of Falls | 11.3 ± 20.10 | 16.5 ± 25.69 |
Cycle ergometry using a recumbent stationary bicycle was used to conduct maximal exercise testing and workload was increased incrementally. Peak work is defined as the workload at which participants reach maximal volition (defined as an inability to continue to exercise due to exhaustion). A positive change from baseline suggests an improvement.
| Watts/kg | Part 2: Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 48 | 0.0397 ± 0.20106 | 0.0963 ± 0.24465 |
The ADL scale examines the ability of participants to complete everyday tasks (e.g., holding a fork, dressing). The ADL is a 9-question assessment, with the total score being the sum of 9 questions. The ADL survey assesses 9 concepts: (1) speech; (2) swallowing; (3) cutting food and handling utensils; (4) dressing; (5) personal hygiene; (6) falling; (7) walking; (8) quality of sitting position; and (9) bladder function. Each of these is rated on a 5-point scale where 0= normal and 4= severe disability/inability to carry out activity independently, for a total possible score of 0 to 36, with higher scores representing greater disability/dependency. A negative change from baseline indicates improvement.
| score on a scale | Part 2: Omaveloxolone 150 mg | Part 2: Placebo |
|---|---|---|
| Part 2: Change From Baseline in the Activities of Daily Living (ADL) Score at Week 48 | -0.222 ± 3.0365 | 1.183 ± 2.5440 |
Collected over From first dose of study drug up to end of OLE period (up to approximately 130 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part 1: Omaveloxolone 10 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part 1: Omaveloxolone 20 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part 1: Omaveloxolone 40 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part 1: Omaveloxolone 80 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part 1: Omaveloxolone 160 mg | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Part 1: Omaveloxolone 300 mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Part 1: Placebo | 0/17 (0%) | 2/17 (11.8%) | 16/17 (94.1%) |
| Part 2: Omaveloxolone 150 mg | 0/51 (0%) | 5/51 (9.8%) | 51/51 (100%) |
| Part 2: Placebo | 0/52 (0%) | 3/52 (5.8%) | 50/52 (96.2%) |
| OLE: Placebo/ Omaveloxolone | 0/106 (0%) | 12/106 (11.3%) | 103/106 (97.2%) |
| OLE: Omaveloxolone/ Omaveloxolone | 0/43 (0%) | 13/43 (30.2%) | 42/43 (97.7%) |
| Event | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | OLE: Placebo/ Omaveloxolone | OLE: Omaveloxolone/ Omaveloxolone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug withdrawal syndromeGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 1/17 | 0/51 | 0/52 | 0/106 | 0/43 |
| Burns third degreeInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 1/17 | 0/51 | 0/52 | 0/106 | 0/43 |
| Left ventricular failureCardiac disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 0/51 | 0/52 | 0/106 | 1/43 |
| Sinus tachycardiaCardiac disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 1/51 | 0/52 | 0/106 | 1/43 |
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 0/51 | 0/52 | 0/106 | 1/43 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 0/51 | 0/52 | 0/106 | 1/43 |
| PainGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 0/51 | 0/52 | 0/106 | 1/43 |
| GastroenteritisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 0/51 | 0/52 | 0/106 | 1/43 |
| Lower respiratory tract infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 0/51 | 0/52 | 0/106 | 1/43 |
| Pilonidal diseaseInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 0/51 | 0/52 | 0/106 | 1/43 |
| Event | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | OLE: Placebo/ Omaveloxolone | OLE: Omaveloxolone/ Omaveloxolone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/6 | 1/6 | 5/6 | 2/6 | 2/6 | 4/12 | 6/10 | 1/17 | 14/51 | 15/52 | 24/106 | 13/43 |
| Covid-19Infections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/10 | 0/17 | 0/51 | 0/52 | 49/106 | 24/43 |
| FatigueGeneral disorders | 3/6 | 0/6 | 0/6 | 0/6 | 2/6 | 1/12 | 0/10 | 2/17 | 11/51 | 7/52 | 13/106 | 7/43 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 | 2/12 | 2/10 | 0/17 | 19/51 | 1/52 | 25/106 | 4/43 |
| HeadacheNervous system disorders | 1/6 | 0/6 | 0/6 | 0/6 | 2/6 | 4/12 | 2/10 | 3/17 | 19/51 | 13/52 | 21/106 | 8/43 |
| ContusionInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/12 | 1/10 | 0/17 | 17/51 | 19/52 | 20/106 | 8/43 |
| NauseaGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 | 1/12 | 2/10 | 1/17 | 17/51 | 7/52 | 22/106 | 7/43 |
| Influenza like illnessGeneral disorders | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/12 | 0/10 | 1/17 | 3/51 | 1/52 | 0/106 | 0/43 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 3/12 | 3/10 | 0/17 | 7/51 | 9/52 | 6/106 | 9/43 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/6 | 1/6 | 0/6 | 0/6 | 0/6 | 1/12 | 2/10 | 0/17 | 9/51 | 10/52 | 28/106 | 9/43 |
Part 1: The Intent-to-treat (ITT) population included all enrolled participants in Part 1, whether or not they received the study drug. Part 2: All Randomized Population (ARP) included all participants randomized, categorized by their randomized treatment group (whether or not they received study drug).
| Age, Continuous(years) | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 25.8 ± 5.98 | 25.5 ± 7.4 | 28.3 ± 6.8 | 27.7 ± 7.53 | 24.3 ± 4.8 | 25.3 ± 6.51 | 25.6 ± 7.24 | 24.4 ± 6.74 | 23.4 ± 6.08 | 24.1 ± 7.85 | 24.5 ± 6.84 |
| Sex: Female, Male(Participants) | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 5 | 1 | 3 | 5 | 5 | 10 | 31 | 17 | 85 |
| Male | 2 | 2 | 1 | 5 | 3 | 7 | 5 | 7 | 20 | 35 | 87 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 |
| Not Hispanic or Latino | 6 | 5 | 6 | 6 | 6 | 12 | 10 | 16 | 49 | 49 | 165 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Omaveloxolone 2.5 mg Followed by 5 mg | Part 1: Omaveloxolone 10 mg | Part 1: Omaveloxolone 20 mg | Part 1: Omaveloxolone 40 mg | Part 1: Omaveloxolone 80 mg | Part 1: Omaveloxolone 160 mg | Part 1: Omaveloxolone 300 mg | Part 1: Placebo | Part 2: Omaveloxolone 150 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 6 | 6 | 6 | 6 | 11 | 10 | 16 | 50 | 50 | 167 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Jan 2015 to primary completion in Oct 2019, 57 months.
Results were first posted in Nov 2022, 3 years after primary completion. A results delay was requested in Oct 2020.
Of 12 phase 2 interventional studies under Friedreich Ataxia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 34. This study's 57 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.